Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 129

1.

Rationale for, and design of, a clinical trial targeting polyamine metabolism for colon cancer chemoprevention.

Gerner EW, Meyskens FL Jr, Goldschmid S, Lance P, Pelot D.

Amino Acids. 2007 Aug;33(2):189-95. Epub 2007 Mar 30. Review.

2.

Effect of alpha-difluoromethylornithine on rectal mucosal levels of polyamines in a randomized, double-blinded trial for colon cancer prevention.

Meyskens FL Jr, Gerner EW, Emerson S, Pelot D, Durbin T, Doyle K, Lagerberg W.

J Natl Cancer Inst. 1998 Aug 19;90(16):1212-8.

3.

Development of difluoromethylornithine (DFMO) as a chemoprevention agent.

Meyskens FL Jr, Gerner EW.

Clin Cancer Res. 1999 May;5(5):945-51. Review.

4.

Phase I chemoprevention study of piroxicam and alpha-difluoromethylornithine.

Carbone PP, Douglas JA, Larson PO, Verma AK, Blair IA, Pomplun M, Tutsch KD.

Cancer Epidemiol Biomarkers Prev. 1998 Oct;7(10):907-12.

5.

A randomized, placebo-controlled trial of low-dose alpha-difluoromethylornithine in individuals at risk for colorectal cancer.

Love RR, Jacoby R, Newton MA, Tutsch KD, Simon K, Pomplun M, Verma AK.

Cancer Epidemiol Biomarkers Prev. 1998 Nov;7(11):989-92.

6.

Nonsteroidal anti-inflammatory drugs stimulate spermidine/spermine acetyltransferase and deplete polyamine content in colon cancer cells.

Turchanowa L, Dauletbaev N, Milovic V, Stein J.

Eur J Clin Invest. 2001 Oct;31(10):887-93.

PMID:
11737227
7.

APC-dependent changes in expression of genes influencing polyamine metabolism, and consequences for gastrointestinal carcinogenesis, in the Min mouse.

Erdman SH, Ignatenko NA, Powell MB, Blohm-Mangone KA, Holubec H, Guillén-Rodriguez JM, Gerner EW.

Carcinogenesis. 1999 Sep;20(9):1709-13.

PMID:
10469614
9.

Dose de-escalation chemoprevention trial of alpha-difluoromethylornithine in patients with colon polyps.

Meyskens FL Jr, Emerson SS, Pelot D, Meshkinpour H, Shassetz LR, Einspahr J, Alberts DS, Gerner EW.

J Natl Cancer Inst. 1994 Aug 3;86(15):1122-30.

10.

Combination chemoprevention of intestinal carcinogenesis in a murine model of familial adenomatous polyposis.

Ignatenko NA, Besselsen DG, Stringer DE, Blohm-Mangone KA, Cui H, Gerner EW.

Nutr Cancer. 2008;60 Suppl 1:30-5. doi: 10.1080/01635580802401317.

PMID:
19003578
11.

Polyamines and cancer: old molecules, new understanding.

Gerner EW, Meyskens FL Jr.

Nat Rev Cancer. 2004 Oct;4(10):781-92. Review.

13.

Polyamines as mediators of APC-dependent intestinal carcinogenesis and cancer chemoprevention.

Rial NS, Meyskens FL, Gerner EW.

Essays Biochem. 2009 Nov 4;46:111-24. doi: 10.1042/bse0460008. Review.

14.

Influence of K-ras activation on the survival responses of Caco-2 cells to the chemopreventive agents sulindac and difluoromethylornithine.

Lawson KR, Ignatenko NA, Piazza GA, Cui H, Gerner EW.

Cancer Epidemiol Biomarkers Prev. 2000 Nov;9(11):1155-62.

15.
16.

Phospho-sulindac (OXT-328) combined with difluoromethylornithine prevents colon cancer in mice.

Mackenzie GG, Ouyang N, Xie G, Vrankova K, Huang L, Sun Y, Komninou D, Kopelovich L, Rigas B.

Cancer Prev Res (Phila). 2011 Jul;4(7):1052-60. doi: 10.1158/1940-6207.CAPR-11-0067. Epub 2011 Apr 4.

17.

Development of difluoromethylornithine as a chemoprevention agent for the management of colon cancer.

Meyskens FL Jr, Gerner EW.

J Cell Biochem Suppl. 1995;22:126-31.

PMID:
8538189
18.

Strategies for colon cancer prevention: combination of chemopreventive agents.

Reddy BS.

Subcell Biochem. 2007;42:213-25. Review.

PMID:
17612053
19.

Modulation of biologic endpoints by topical difluoromethylornithine (DFMO), in subjects at high-risk for nonmelanoma skin cancer.

Einspahr JG, Nelson MA, Saboda K, Warneke J, Bowden GT, Alberts DS.

Clin Cancer Res. 2002 Jan;8(1):149-55.

20.

Supplemental Content

Support Center